

## NEW BIOMARKERS FOR DIAGNOSIS AND MONITORING OF MULTIPLE SCLEROSIS

This invention provides an in-vitro method (biomarkers) to diagnose and/or monitor multiple sclerosis patients.

### **TYPE OF DEVELOPMENT**

Diagnostic and/or prognostic tool.

### **DESCRIPTION**

Multiple sclerosis (MS) is a demyelinating and autoimmune disease that affects over 2.5 million people all over the world. MS is the second cause of disability in adults aged 20-40. It entails a high cost for the health system, mainly because of the treatments, disease chronicity and the disability it causes.

The disease is diagnosed following a set of criteria (McDonald criteria); however, other tools are required to improve these criteria in order to achieve early diagnosis, so this is a priority in MS research.

In this sense, a marker that allows monitoring of patients' response to drugs is required.

There are currently no short-term biomarkers and most of the time the sample required must be of cerebrospinal fluid.

This invention offers a new method to diagnose MS and monitor patients' response to drugs.

### **ADVANTAGES**

- Non-invasive method (blood sample).
- Simple, fast and reliable.

### **USE**

- Diagnosis of multiple sclerosis.
- Monitoring of MS patients' response to drugs.

### **PROTECTION**

**Spanish Patent Application (P202030782)**

**Priority Date:** 28/07/2020

**Applicants:** Administration of the Autonomous Community of the Basque Country.

### **COOPERATION GOAL**

- Company interested in the license and commercialisation of the product.

### **CONTACT**

Amaia Albandoz

Research Results Transfer Office (OTRI)

[amaia@bioef.eus](mailto:amaia@bioef.eus) Tel.: +34 944 53 68 49